XNASPULM
Market cap21mUSD
Jan 08, Last price
5.99USD
1D
-4.31%
1Q
178.60%
Jan 2017
-94.92%
IPO
-99.82%
Name
Pulmatrix Inc
Chart & Performance
P/E
—
P/S
3.00
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
77.66%
Rev. gr., 5y
116.62%
Revenues
7m
+20.21%
Net income
-14m
L-24.59%
CFO
-16m
L-17.42%
Earnings
Mar 26, 2025
Profile
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2015‑03 | |
| Income | ||||||||||
Revenues | 7,298 20.21% | 6,071 17.45% | ||||||||
Cost of revenue | 37,556 | 26,563 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (30,258) | (20,492) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | (111) | |||||||||
Tax Rate | ||||||||||
NOPAT | (30,258) | (20,381) | ||||||||
Net income | (14,121) -24.59% | (18,725) -16.80% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 53 | 1,078 | ||||||||
BB yield | -0.78% | -8.06% | ||||||||
| Debt | ||||||||||
Debt current | 858 | 857 | ||||||||
Long-term debt | 17,083 | 857 | ||||||||
Deferred revenue | 3,727 | 4,822 | ||||||||
Other long-term liabilities | ||||||||||
Net debt | (1,232) | (35,386) | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | (15,985) | (19,356) | ||||||||
CAPEX | (676) | (86) | ||||||||
Cash from investing activities | (676) | (86) | ||||||||
Cash from financing activities | 53 | 1,230 | ||||||||
FCF | (40,780) | (18,912) | ||||||||
| Balance | ||||||||||
Cash | 19,173 | 35,628 | ||||||||
Long term investments | 1,472 | |||||||||
Excess cash | 18,808 | 36,796 | ||||||||
Stockholders' equity | (287,597) | (273,476) | ||||||||
Invested Capital | 318,504 | 310,264 | ||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 3,652 | 3,448 | ||||||||
Price | 1.86 -52.06% | 3.88 -55.67% | ||||||||
Market cap | 6,793 -49.22% | 13,377 -43.57% | ||||||||
EV | 5,561 | (22,009) | ||||||||
EBITDA | (28,783) | (18,947) | ||||||||
EV/EBITDA | 1.16 | |||||||||
Interest | 111 | |||||||||
Interest/NOPBT | ||||||||||